Home / News / Pfizer’s COVID pill Paxlovid has profound effect in seniors, jury still out for younger adults.
Recent Posts
- What to know about the upcoming flu season, vaccine
- Beyond the Opioid Epidemic: Scientist Seeks to Develop non-Addictive Treatment for Pain.
- Avoiding a “Tripledemic” This Winter.
- Overdose deaths from fentanyl combined with stimulants increased 50-fold since 2010.
- Flu season is approaching. Here’s what to expect in N.J.
A new study is sure to add another layer of intrigue surrounding Pfizer’s COVID-19 pill Paxlovid. In the study, based on data collected from 109,000 patients at a large Israeli health system, the drug appeared highly effective in seniors. Researchers found that those 65 and older who got the drug shortly after infection had a roughly 75% lower chance of being hospitalized, a rate which is consistent with earlier results. However, those markedly decreased odds of hospitalization were not seen in the 40-64 age cohort, where researchers reported “no evidence of benefit.” That was the gist of their study writeup, which appeared in the New England Journal of Medicine, and the storyline was duly repeated countless times in mainstream media coverage. To read the full story.